News
Stay up to date
Follow the latest on our journey, as we are living innovation!
We are a biotechnology company committed to improving the lives of people with severe diseases.
On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities and pursue new transformational business development transactions using its available cash resources. This intention followed a comprehensive review of strategic alternatives, including a potential divestiture, conducted during 2025. Following completion of the required consultations with the works councils in Belgium and the Netherlands, the Board announced in January 2026 its decision to initiate the wind-down of the Company’s cell therapy activities. This step marks the transition from strategic evaluation to execution and is intended to enhance operational efficiency while enabling Galapagos to focus its resources on building a pipeline of novel therapeutics through strategic business development transactions, under the leadership of its new management team.
PIPELINE
We focus on delivering best-in-class medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need.
Meet the members of our Executive Committee and our Management Team. They are driving innovation to deliver life-changing treatments for patients worldwide, together.
News
Follow the latest on our journey, as we are living innovation!
Investors
Looking for the latest presentations, upcoming events, and financial highlights?